Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8BR7

Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839

This is a non-PDB format compatible entry.
Summary for 8BR7
Entry DOI10.2210/pdb8br7/pdb
DescriptorInterleukin-1 receptor-associated kinase 4, 3-nitro-~{N}-[2-[2-oxidanylidene-2-[4-(phenylcarbonyl)piperazin-1-yl]ethyl]indazol-5-yl]benzamide (3 entities in total)
Functional Keywordsirak4, kinase, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight67598.20
Authors
Primary citationBothe, U.,Gunther, J.,Nubbemeyer, R.,Siebeneicher, H.,Ring, S.,Bomer, U.,Peters, M.,Rausch, A.,Denner, K.,Himmel, H.,Sutter, A.,Terebesi, I.,Lange, M.,Wengner, A.M.,Guimond, N.,Thaler, T.,Platzek, J.,Eberspacher, U.,Schafer, M.,Steuber, H.,Zollner, T.M.,Steinmeyer, A.,Schmidt, N.
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839 .
J.Med.Chem., 67:1225-1242, 2024
Cited by
PubMed Abstract: Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, (zabedosertib) and , starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.
PubMed: 38228402
DOI: 10.1021/acs.jmedchem.3c01714
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.119 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon